Puma Biotechnology (NASDAQ:PBYI – Get Rating) and Soligenix (NASDAQ:SNGX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.
Earnings and Valuation
This table compares Puma Biotechnology and Soligenix’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Puma Biotechnology||$228.00 million||0.66||$5.14 million||$0.11||29.09|
Puma Biotechnology has higher revenue and earnings than Soligenix.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and price targets for Puma Biotechnology and Soligenix, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Puma Biotechnology currently has a consensus target price of $8.00, indicating a potential upside of 150.00%. Given Puma Biotechnology’s higher probable upside, equities research analysts clearly believe Puma Biotechnology is more favorable than Soligenix.
Insider and Institutional Ownership
60.6% of Puma Biotechnology shares are held by institutional investors. Comparatively, 7.2% of Soligenix shares are held by institutional investors. 21.2% of Puma Biotechnology shares are held by insiders. Comparatively, 4.0% of Soligenix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Puma Biotechnology has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500.
Puma Biotechnology beats Soligenix on 9 of the 11 factors compared between the two stocks.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.